Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Item 9 Labs Corp. (INLB)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
2727 North 3rd Street 85004
Phoenix, AZ, US
Phoenix, AZ, US
CEO
Jeffrey I. Rassas
Website
item9labscorp.com
IPO
2012-01-25
CIK 1500123 ISIN US46564C2035
Description
Based in the United States, Item 9 Labs Corp. operates as a comprehensive cannabis company, encompassing both vertical integration in cannabis operations and the franchising of dispensaries. The firm produces a wide spectrum of cannabis and related goods, such as raw flower, various concentrates, distillates, and necessary hardware. These cannabis and derived technologies and products are then supplied to consumers in Arizona via licensed retail dispensaries. Complementing its production activities, the company also develops and offers medical and adult-use cannabis dispensary franchises under its distinct Unity Rd brand. The main office for Item 9 Labs Corp. is found in Phoenix, Arizona.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
13.8K
Beta
0.18
Float Shares
524.14M
Free Float %
74.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.90% | -100.00% | -99.93% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.03
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-0.8% Q2'23: +1.8% (vs Q2'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-135.7% Q2'23: -1.9% (vs Q2'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-107.2% Q2'23: +1.7% (vs Q2'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-113.8% Q2'23: -59.0% (vs Q2'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-27.6% Q2'23: -13.7% (vs Q2'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+21.8% Q2'23: +5.9% (vs Q2'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.22× Q2'23: -3.38× (vs Q2'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
|---|---|---|---|---|
| Revenue |
21.94M
est: 23.34M (-6.0%)
|
21.76M
est: 21.80M (-0.2%)
|
23.50M
est.
|
30.00M
est.
|
| EBITDA |
-4.35M
est: -14.87M (+70.7%)
|
-22.83M
est: -13.89M (-64.4%)
|
-14.97M
est.
|
-19.11M
est.
|
| EBIT |
-5.61M
est: -15.87M (+64.6%)
|
-24.75M
est: -14.82M (-67.0%)
|
-15.98M
est.
|
-20.40M
est.
|
| Net Income |
-10.91M
est: -956.9K (-1,039.7%)
|
-31.14M
est: -31.58M (+1.4%)
|
-12.44M
est.
|
-7.66M
est.
|
| SGA |
11.06M
est: 16.03M (-31.0%)
|
18.83M
est: 14.97M (+25.8%)
|
16.14M
est.
|
20.60M
est.
|
| EPS |
-0.14
est: -0.01 (-1,300.0%)
|
-0.33
est: -0.33 (+0.0%)
|
-0.13
est.
|
-0.08
est.
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.24M
OE per share TTM
-0.06
Owner's Yield
-61,300.26%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
87.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
2
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-14 | Taylor Lawrence X. III | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-14 | Kutscher Eric | Director | — | D | Common Stock | 0 | 0.00 | — | 20,906 | — | ↗ |
| 2021-05-08 | Skalla Bryce | Director / Officer | — | D | Option | 2,500 | 2.40 | 6.0K | 0 | — | ↗ |
| 2021-05-08 | Miller Ronald L. Jr. | Director | — | D | Option | 2,500 | 2.40 | 6.0K | 0 | — | ↗ |
| 2021-05-08 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Officer | — | D | Option | 2,500 | 2.40 | 6.0K | 0 | — | ↗ |
| 2020-07-31 | KESKEY MICHAEL P | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-04-01 | Bowden Douglas P | Director | — | I | Warrants | 3,500,000 | 1.00 | 3.50M | 0 | — | ↗ |
| 2020-03-23 | Bowden Douglas P | Director | — | I | Warrants | 5,000,000 | 0.75 | 3.75M | 0 | — | ↗ |
| 2020-02-04 | Bowden Douglas P | Director | — | I | Common Stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
| 2019-09-09 | Skalla Bryce | Director / Officer | G-Gift | D | Common | 286,842 | 0.00 | — | 5,217,036 | — | ↗ |
| 2019-09-06 | Poirier Andrew | 10% Owner | G-Gift | D | Common | 360,000 | 0.00 | — | 7,618,045 | — | ↗ |
| 2019-09-06 | Dugan Patrick Sean | 10% Owner | G-Gift | D | Common | 80,000 | 0.00 | — | 8,144,712 | — | ↗ |
| 2019-08-26 | Wolven Christopher Leland | Officer | — | D | Common Stock | 0 | 0.00 | — | 259,615 | — | ↗ |
| 2019-08-26 | Skalla Bryce | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 5,503,878 | — | ↗ |
| 2019-08-26 | Poirier Andrew | 10% Owner | — | D | Common | 0 | 0.00 | — | 7,978,045 | — | ↗ |
| 2019-08-26 | Miller Ronald L. Jr. | Director | — | I | Common Stock | 0 | 0.00 | — | 2,126 | — | ↗ |
| 2019-08-26 | Mikkelsen Robert E | Officer | — | D | Common | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-08-26 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Officer | — | D | Common | 0 | 0.00 | — | 1,788,903 | — | ↗ |
| 2019-08-26 | Gullickson Sara | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 2,305,000 | — | ↗ |
| 2019-08-26 | Dugan Patrick Sean | 10% Owner | — | D | Common | 0 | 0.00 | — | 8,224,712 | — | ↗ |
| 2019-08-26 | Bowden Andrew Douglas | Director | — | I | Common | 0 | 0.00 | — | 5,000,000 | — | ↗ |
| 2016-09-30 | Miller Ronald L. Jr. | Director | — | I | Common Stock | 0 | 0.00 | — | 42,500 | — | ↗ |
| 2016-09-30 | COHEN DANIEL E MD | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-03-08 | Miller Ronald L. Jr. | Director | — | D | Option | 17,500 | 3.00 | 52.5K | 0 | — | ↗ |
| 2016-03-08 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Officer | — | D | Option | 16,667 | 3.00 | 50.0K | 0 | — | ↗ |
| 2016-03-01 | Smith Jessica L | Officer | A-Award | A | Option | 33,333 | 0.15 | 5.0K | 400,000 | — | ↗ |
| 2016-03-01 | Miller Ronald L. Jr. | Director | A-Award | A | Option | 150,000 | 0.15 | 22.5K | 600,000 | — | ↗ |
| 2016-03-01 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Director / Officer | A-Award | A | Option | 111,111 | 0.15 | 16.7K | 2,222,221 | — | ↗ |
| 2015-09-30 | Smith Jessica L | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-09-30 | Miller Ronald L. Jr. | Director | — | I | Common Stock | 0 | 0.00 | — | 42,500 | — | ↗ |
| 2014-09-30 | Smith Jessica L | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-09-30 | Miller Ronald L. Jr. | Director | — | D | Common Stock | 0 | 0.00 | — | 50,023 | — | ↗ |
| 2014-09-05 | Smith Jessica L | Officer | A-Award | A | Option | 33,334 | 0.25 | 8.3K | 266,667 | — | ↗ |
| 2014-09-05 | Miller Ronald L. Jr. | Director | A-Award | A | Option | 150,000 | 0.25 | 37.5K | 450,000 | — | ↗ |
| 2014-09-05 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Director / Officer | A-Award | A | Option | 111,111 | 0.25 | 27.8K | 1,444,444 | — | ↗ |
| 2014-08-21 | Miller Ronald L. Jr. | Director | P-Purchase | A | Common Stock | 4,000 | 0.17 | 680.00 | 50,023 | — | ↗ |
| 2014-08-20 | Miller Ronald L. Jr. | Director | P-Purchase | A | Common Stock | 523 | 0.16 | 83.68 | 46,023 | — | ↗ |
| 2014-08-19 | Miller Ronald L. Jr. | Director | P-Purchase | A | Common Stock | 1,000 | 0.16 | 160.00 | 45,500 | — | ↗ |
| 2014-05-19 | Miller Ronald L. Jr. | Director | P-Purchase | A | Common Stock | 21,250 | 0.12 | 2.6K | 44,500 | — | ↗ |
| 2013-10-04 | Miller Ronald L. Jr. | Director | — | D | Option | 7,500 | 2.20 | 16.5K | 0 | — | ↗ |
| 2013-10-04 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Officer | — | D | Option | 16,667 | 2.20 | 36.7K | 0 | — | ↗ |
| 2013-09-30 | Smith Jessica L | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-09-30 | Miller Ronald L. Jr. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-09-30 | Henderson Lorrie | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-09-30 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-01-25 | Miller Ronald L. Jr. | Director | — | D | Option | 7,500 | 6.00 | 45.0K | 0 | — | ↗ |
| 2013-01-25 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Officer | — | D | Option | 50,000 | 6.00 | 300.0K | 0 | — | ↗ |
| 2012-06-07 | HAYJOUR FAMILY LIMITED PARTNERSHIP | Director / Officer | — | D | Common Stock, $0.0001 Par Value | 0 | 0.00 | — | 2,292,561 | — | ↗ |
| 2011-12-14 | Larson Christopher | — | — | I | Common Stock | 0 | 0.00 | — | 437,500 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-255.2K
Shares Outstanding
701.81M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jeffrey I. Rassas | Strategic Advisor & Director | 176.6K | male |
| Cory Carter | Senior Vice President of Cultivation | — | male |
| Jayne Levy | Senior Vice President of Communications | — | female |
| Kyle Jennings | Vice President of Marketing | — | — |
| Mark Busch | Senior Vice President of Corporate Development | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for INLB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
